Search review questions

HRQoL, SGRQ (total score) Scale from: 0 to 100. SGRQ comprises responses to 50 items, 0 being the best possible score and 100 the worst. WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger…

All‐cause mortality WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger…

Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger…

Any adverse event WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger…

FEV1 (mL) WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The two larger…

Treatment failure within 4 weeks ‐ current drugs only · exacerbations of COPD

Adverse events ‐ overall (any adverse events not specified) · exacerbations of COPD

All‐cause mortality · exacerbations of COPD

Treatment failure within 4 weeks ‐ current drugs only ‐ inpatient · exacerbations of COPD

Treatment failure within 4 weeks ‐ drugs not currently used ‐ ICU · exacerbations of COPD

Duration of hospital stay (days) ‐ inpatients · exacerbations of COPD

Duration of hospital stay (days) ‐ ICU patients · exacerbations of COPD

All‐cause mortality ‐ inpatients · exacerbations of COPD

All‐cause mortality ‐ ICU patients · exacerbations of COPD

Adverse events ‐ diarrhoea · exacerbations of COPD

Peripheral muscle force · COPD

Peripheral muscle endurance/fatigability · COPD

Thigh muscle size · COPD

Exercise capacity · COPD

Functional performance · COPD

Symptoms of dyspnoea reported on completion of an exercise test · COPD

Health‐related quality of life · COPD

Minor adverse events assessed: related to intervention only (e.g. redness) · COPD

Peripheral muscle endurance/fatigability · COPD

Thigh muscle size · COPD

Exercise capacity · COPD

Functional performance · COPD

Symptoms of dyspnoea reported on completion of an exercise test · COPD

Health‐related quality of life · COPD

Minor adverse events assessed: related to intervention only (e.g. redness) · COPD

Peripheral muscle force · COPD

Change in lung function (FVC % predicted) · people with connective tissue disease‐associated interstitial lung disease

Adverse events: pneumonia 12‐month · people with connective tissue disease‐associated interstitial lung disease

Adverse events: anaemia 12‐month · people with connective tissue disease‐associated interstitial lung disease

Adverse events: thrombocytopenia 12‐month · people with connective tissue disease‐associated interstitial lung disease

Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease

All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease

Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease

Adverse events: pneumonia 12‐month · people with connective tissue disease‐associated interstitial lung disease

Adverse events: haematuria 12‐month · people with connective tissue disease‐associated interstitial lung disease

Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease

All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease

Change in lung function (FVC % predicted) · people with connective tissue disease‐associated interstitial lung disease

Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease

Adverse events: leukopenia 12‐month · people with connective tissue disease‐associated interstitial lung disease

Exacerbations requiring steroids or antibiotics or both: number of participants · people with COPD

Non‐fatal serious adverse events · people with COPD

Hospital admissions due to exacerbations: number of participants · people with COPD

Improvement in symptoms: number of participants with clinically significant improvement: using TDI focal score (≥ 1 unit) · people with COPD

Change in lung function: from baseline in trough FEV1 (L) · people with COPD